Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a new pill calm brain inflammation and slow Parkinson's-Linked sleep disorder?

NCT ID NCT05904717

First seen Jun 07, 2026 · Last updated Jun 18, 2026 · Updated 5 times

Summary

This study tests whether an oral drug called PXS-4728A can reduce brain inflammation in 40 adults aged 50-80 with isolated REM sleep behavior disorder (iRBD), a condition often leading to Parkinson's disease. Participants receive either the drug or a placebo for 12 weeks, and brain scans measure inflammation changes. The goal is to see if the drug is safe and can slow disease progression.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REM SLEEP BEHAVIOR DISORDER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Clinical Neuroscience Nuffield Department of Clinical Neurosciences

    Oxford, United Kingdom

  • Cognitive Neuroscience Brain & Mind Centre

    Camperdown, Sydney, 2050, Australia

  • Parkinsons Disease Research Clinic - Macquarie University

    Macquarie, New South Wales, 2109, Australia

Conditions

The condition(s) this trial relates to.

REM sleep behavior disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.